coronaviru
regist
china
clinic
trial
registri
chictr
provid
data
base
inform
refer
clinic
treatment
sinc
new
type
infecti
diseas
ebola
viru
diseas
human
infect
highli
pathogen
avian
influenza
zika
viru
diseas
appear
china
serious
threaten
peopl
health
public
health
secur
therefor
studi
collat
analyz
registr
clinic
studi
provid
informationbas
data
foundat
inform
refer
curb
spread
epidem
check
clinic
research
index
issu
chictr
center
search
chictr
databas
keyword
novel
coronaviru
count
registr
inform
februari
extract
follow
inform
registr
statu
date
registr
date
complet
region
registr
etc
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
datasetther
disagr
two
review
dataset
studi
basic
research
characterist
research
type
intervent
method
fund
sourc
research
stage
defin
descript
analysi
registr
time
trend
geograph
distribut
registr
volum
reflect
overal
trend
clinic
research
descript
statist
calcul
investig
percentag
distribut
item
studiedth
frequenc
calcul
multicent
research
institut
base
statist
respons
unit
studi
durat
calcul
chictr
studi
execut
time
chisquar
test
signific
level
perform
studi
possibl
differ
design
characterist
research
type
intervent
method
fund
sourc
research
stage
chisquar
test
statist
analyz
main
featur
exclud
featur
analys
addit
studi
key
inclusionexclus
criteria
item
rule
chisquar
test
statist
analysi
perform
use
softwar
p
consid
statist
signific
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
total
clinic
studi
regist
chictr
overal
number
registr
increas
steadili
figur
number
registr
februari
small
number
registr
quickli
increas
februari
reach
peak
februari
januari
china
chictr
center
regist
first
clinic
studi
intervent
method
cmt
treatment
first
tcm
clinic
studi
regist
januari
first
bi
studi
regist
februari
bei
studi
first
regist
februari
statist
date
total
provinc
municip
nationwid
particip
clinic
studi
figur
nation
registr
volum
rank
first
hubei
provinc
follow
guangdong
provinc
zhejiang
provinc
sichuan
provinc
tie
third
place
tongji
hospit
tongji
medic
colleg
huazhong
univers
scienc
technolog
regist
hospit
shown
tabl
studi
intervent
studi
observ
studi
studi
treat
cmt
treat
bi
treat
tcm
treat
beith
earli
stage
account
studi
studi
late
stage
research
mainli
fund
public
research
recruit
howev
studi
receiv
ethic
approv
confirm
data
manag
committe
tabl
studi
multicent
studi
studi
particip
studi
studi
complet
within
month
complet
within
month
studi
use
random
assign
studi
lack
inform
blind
tabl
chisquar
test
reveal
signific
differ
design
characterist
depend
type
studi
item
particip
number
studi
durat
studi
assign
blind
method
number
particip
intervent
observ
studi
concentr
intervent
observ
studi
complet
within
month
intervent
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
studi
randomli
assign
group
observ
continu
intervent
studi
blind
signific
differ
could
seen
dimens
multicent
studi
particip
numb
studi
durat
studi
assign
four
intervent
methodsonli
cmt
studi
multicent
studi
convers
bei
studi
multicent
studi
account
largest
proportionth
number
particip
mainli
account
cmt
subject
less
bi
subject
less
tcm
bei
subject
studi
period
mainli
focus
cmt
studi
complet
within
month
bi
within
tcm
within
bei
studi
longer
monthfor
studi
assign
cmt
bi
tcm
bei
studi
random
cmt
bi
tcm
blind
studi
signific
differ
dimens
studi
assign
earli
late
studi
earli
stage
late
stage
randomli
assign
group
howev
signific
differ
main
research
dimens
differ
fund
sourc
p
drug
involv
cmt
bi
treatment
research
summar
frequenc
research
record
drug
record
clinic
trial
intervent
drug
treatment
cmt
studi
top
three
drug
studi
frequenc
chloroquin
lopinavirritonavir
iifn
bi
studi
top
three
drug
studi
frequenc
cell
therapi
plasma
therapi
thymosin
mpab
among
cell
therapi
mesenchym
stem
cell
cell
therapi
cord
blood
mononuclear
cell
cell
therapi
menstrual
bloodderiv
stem
cell
cell
therapi
natur
killer
cell
figur
tabl
summari
high
research
frequenc
drug
cmt
bi
achiev
inform
share
clinic
trial
key
acceler
transform
clinic
resourc
promot
scientif
breakthrough
face
public
safeti
crisi
outbreak
time
share
inform
even
import
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
provid
realtim
guidanc
prevent
control
epidem
assess
develop
trend
effect
intervent
measur
war
epidem
epidem
prevent
strategi
close
relat
import
measur
improv
transpar
clinic
trial
includ
share
subject
origin
data
standard
trial
design
registr
implement
present
china
clinic
trial
registr
polici
implement
registr
requir
registr
accord
chictr
registr
guidelin
chictr
registr
guidelin
divid
research
type
categori
intervent
studi
prevent
studi
diagnost
test
observ
studi
etc
howev
ambigu
registr
guidelin
classifi
studi
natur
purpos
accord
intern
standard
may
clear
classifi
intervent
observ
order
regul
registr
detail
provid
random
procedur
blind
methodw
found
intervent
studi
use
random
alloc
low
blind
rate
lack
informationth
possibl
reason
difficult
implement
blind
method
epidem
situat
may
also
incomplet
inform
half
studi
indic
blind
method
informationmiss
inform
mean
inform
size
studi
avail
advers
affect
transpar
registr
result
show
half
studi
confirm
data
manag
committe
low
blind
rate
lack
inform
may
relat
detect
guidanc
data
manag
committe
strengthen
improv
qualiti
research
design
worth
note
studi
fail
ethic
verificational
humanori
clinic
trial
must
case
follow
helsinki
declar
becom
consensu
medic
commun
follow
basic
ethic
principl
doctor
provid
medic
care
best
interest
patient
ensur
subject
chictr
center
issu
warn
request
supplementari
inform
fail
unit
reviewedmed
ethic
review
strictli
abid
review
work
content
ethic
review
method
biomed
research
involv
human
two
suggest
undertak
experiment
project
match
actual
capabl
design
experiment
scheme
appropri
research
method
must
select
base
natur
problem
solv
februari
overal
number
regist
clinic
studi
riseth
possibl
reason
china
alreadi
initi
firstlevel
respons
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
major
public
health
emerg
conduct
relev
clinic
trial
critic
epidem
prevent
control
addit
order
cooper
epidem
prevent
control
work
mani
nation
drug
clinic
trial
institut
gcp
china
establish
detail
work
guidelin
guidelin
effect
speed
clinic
trial
reviewfrom
statist
analysi
china
geograph
distribut
found
number
regist
provinc
hubei
provinc
rank
first
number
regist
provinc
close
higher
provinc
possibl
reason
epidem
mainli
concentr
wuhan
hubei
provinc
china
largescal
epidem
outbreak
remot
provinc
rel
ncp
patient
found
signific
differ
dimens
studi
design
characterist
differ
studi
typesth
result
show
compar
observ
studi
intervent
studi
fewer
particip
howev
observ
studi
design
complet
within
month
design
reflect
intervent
studi
intervent
studi
complet
month
similarli
compar
observ
studi
intervent
studi
use
random
alloc
result
impli
differ
intervent
impact
design
clinic
trial
design
clinic
trial
give
prioriti
timeli
trial
sampl
size
need
consid
balanc
clinic
statist
signific
estim
volum
reflect
reliabl
repeat
research
result
public
health
emerg
allow
time
exploratori
clinic
research
histor
data
sampl
size
estim
trial
may
encount
unpreced
problemssom
scholar
propos
whether
possibl
reduc
requir
sampl
size
reduc
power
increas
type
error
rate
complet
clinic
trial
soon
possibl
approach
requir
varieti
tradeoff
regul
sponsor
research
addit
studi
period
also
timeeffect
clinic
studi
long
may
make
much
sens
term
public
health
emerg
respond
outbreak
statist
data
seen
time
limit
complet
clinic
studi
concentr
within
month
studi
complet
within
month
clinic
research
deal
epidem
race
viru
epidem
time
limit
seem
long
possibl
conduct
midterm
analysi
adapt
new
design
method
clinic
trial
statist
need
continu
develop
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
base
actual
need
addit
prevent
control
epidem
vaccin
drug
two
major
weapon
overcom
epidemicth
previou
sarscov
epidem
influenza
epidem
ebola
epidem
west
africa
basic
approv
market
end
epidem
lag
similarli
develop
specif
drug
also
difficultth
old
medicin
new
way
increas
indic
conduct
clinic
research
may
import
mean
respond
current
epidem
new
coronari
viru
pneumonia
diagnosi
treatment
scheme
trial
version
hereinaft
refer
scheme
state
current
effect
drug
treat
ncp
patient
drug
lopinavir
ritonavir
interferon
abidol
chloroquin
phosphat
tri
effect
need
confirm
clinic
studiesin
registr
trial
main
treatment
drug
therapi
account
among
cmt
tcm
studi
rel
bi
studiesth
frequent
studi
cmt
chloroquin
phosphatechloroquin
phosphat
antimalari
drug
market
mani
scheme
emphas
import
role
tcm
treatment
pathogen
factor
mechan
tcm
treat
caus
addit
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
multitarget
regul
bodi
immun
system
therapeut
effect
cytokin
studi
limit
data
studi
deriv
chictr
may
databas
contain
clinic
studi
time
limit
research
registr
short
relev
registr
inform
fill
truli
reflect
true
quantiti
level
howev
innov
articl
summar
analyz
registr
chictr
clinic
research
time
manner
reflect
research
statu
develop
trend
clinic
trial
field
timeeffect
problem
unclear
classif
research
type
irregular
registr
behavior
also
within
studi
research
heterogen
exist
variou
dimens
differ
research
type
intervent
method
research
stage
lead
signific
differ
dimens
studi
final
statist
highfrequ
research
drug
provid
treatment
option
evidencebas
evid
clinic
practic
authorfund
grant
medrxiv
licens
display
preprint
perpetu
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
